181 related articles for article (PubMed ID: 20979938)
1. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Guo HF; Su HL; Mao JJ; Sun C; Wang J; Zhou X
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):776-8. PubMed ID: 20979938
[TBL] [Abstract][Full Text] [Related]
2. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
[No Abstract] [Full Text] [Related]
3. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
5. "IM iD"eally treating multiple myeloma.
Lacy MQ
Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
[TBL] [Abstract][Full Text] [Related]
6. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Fonseca R; Rajkumar SV
Clin Lymphoma Myeloma; 2008 Oct; 8(5):315-7. PubMed ID: 18854289
[TBL] [Abstract][Full Text] [Related]
7. Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Saboo SS; Fennessy F; Benajiba L; Laubach J; Anderson KC; Richardson PG
J Clin Oncol; 2012 Jul; 30(20):e175-9. PubMed ID: 22689802
[No Abstract] [Full Text] [Related]
8. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Takeda Y; Sakaida E; Nakaseko C
Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
11. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A
Cancer; 2011 May; 117(9):1884-90. PubMed ID: 21509765
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Hughes M; Micallef-Eynaud P
Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
[TBL] [Abstract][Full Text] [Related]
14. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
15. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Chim CS
Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
[No Abstract] [Full Text] [Related]
16. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
19. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
Shen Y; Zhou X; Wang Z; Yang G; Jiang Y; Sun C; Wang J; Tong Y; Guo H
Leuk Res; 2011 Feb; 35(2):147-51. PubMed ID: 20832859
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Howman R; Thakerer A; Pitman M; Ding N; Thompson PA; Khot A; Harrison SJ
Leuk Lymphoma; 2010 Dec; 51(12):2299-302. PubMed ID: 20929329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
